Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS
0 ভিউ
• 07/16/23
0
0
বসান
administrator
সাবস্ক্রাইবার
Visit http://www.ecancer.org for more
Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
আরো দেখুন
ফেসবুক মন্তব্য
SORT BY-
শীর্ষ মন্তব্য
-
সর্বশেষ মন্তব্য